Pfizer’s second quarter results were well received by the market, as the company outperformed Wall Street’s expectations for ...

Pfizer (PFE) topped second quarter expectations, but looming Trump-era pharmaceutical tariffs remain a concern. Pfizer CEO ...

As investors and industry watchers juggle the twin possibilities of pharmaceutical import tariffs and potential drug pricing ...

CEO Albert Bourla said Tuesday he has a "special relationship" with President Trump, cemented during the COVID-19 pandemic ...

Albert Bourla confirmed that he called President Donald Trump after receiving a letter asking Pfizer and a clutch of other ...

Pfizer (NYSE: PFE) is a case in point, with its forward dividend yield of 7%. Although the stock is a favorite for many ...

Pfizer CEO Albert Bourla is expected at a pro-Trump fundraiser on Friday, sources told CBS News, one day after the president ...

Pfizer Inc. announced its board of directors has unanimously elected Dr Albert Bourla, 56, Pfizer's chief operating officer (COO), to succeed Ian Read as CEO effective January 1, 2019. Ian Read will ...

Pfizer CEO Albert Bourla discusses the major mobilization to deliver a Covid-19 vaccine in record speed, and what it means for medical research, with WSJ's health and science coverage chief ...

Pfizer Inc. raised its profit forecast for the year, with the drugmaker’s ongoing cost cuts helping to make up for a lack of ...

Chief Executive Albert Bourla says he is hopeful about finding a solution in response to Trump’s demand for price cuts.

Pharma giant Pfizer has appointed a new chief operating officer in the form of Albert Bourla, who has been the group president of Pfizer’s innovative health business since the beginning of 2016. Prior ...